๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A Phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma

โœ Scribed by Edward F. McClay; Mary-Eileen T. McClay; Jeffery A. Jones; Paul J. Winski; Randolf D. Christen; Stephen B. Howell; Philip D. Hall

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
97 KB
Volume
79
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

by 40 mg to the MTD in groups of 3 patients. DDP (80 mg/m 2 ) was begun on Day ogy/Oncology, Hollings Cancer Center, Medical 2 and repeated weekly for a total of 3 weeks. During Week 4, the patients were University of South Carolina, Charleston, South not treated with DDP but instead evaluated for response. If disease stabilization Carolina.

or regression was documented, the patients received a second 3-week cycle of

๐Ÿ“œ SIMILAR VOLUMES

Phase II study of high-dose tamoxifen (N
Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma
โœ Edward T. Creagan; James N. Ingle; David L. Ahmann; Stephanie J. Green ๐Ÿ“‚ Article ๐Ÿ“… 1982 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 206 KB ๐Ÿ‘ 1 views

Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reas

High-dose tamoxifen added to concurrent
High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma
โœ Steven J. O'Day; Peter D. Boasberg; Tim S. Kristedja; Maureen Martin; He-Jing Wa ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 130 KB ๐Ÿ‘ 1 views

## Background: In vitro cell culture data and preclinical models suggest that tamoxifen modulates tumor cell sensitivity to a wide range of therapeutic agents. in the current study, the authors examined whether high-dose tamoxifen (hdt) improved the overall and complete response in patients with me

A phase III randomized trial of dacarbaz
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma
โœ Sanjiv S. Agarwala; William Ferri; William Gooding; John M. Kirkwood ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 90 KB ๐Ÿ‘ 1 views

## BACKGROUND. Metastatic melanoma is a disease associated with a poor prognosis, and dacarbazine is still the reference agent. The authors conducted a randomized trial to test the benefit of adding tamoxifen to dacarbazine and carboplatin chemotherapy for previously untreated patients with metast